Role of inflammation in atherogenesis;El papel de la inflamación en la aterogénesis. Revisión

Investigacion Clinica

Volumn 50, Issue 1, 2009, Pages 109-129

  Rodríguez, Glacelidys ^a   Mago, Neil ^a   Rosa, Francisco ^a  

^a Universidad de Oriente Nucleo Bolivar   (Venezuela)

Author keywords

Atherogenesis; Cytokines; Inflammation; Oxidation

Indexed keywords

AUTOANTIGEN; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; HEAT SHOCK PROTEIN; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPROTEIN; PROTEOGLYCAN; SCAVENGER RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ARTERY INTIMA; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL FUNCTION; CELL INTERACTION; CYTOKINE RELEASE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR MATRIX; FOAM CELL; INFLAMMATION; LEUKOCYTE; MACROPHAGE; PHAGOCYTOSIS; PROGNOSIS; PROTEIN MODIFICATION; REVIEW; T LYMPHOCYTE; TH1 CELL; ANIMAL; HUMAN; IMMUNOLOGY; INTIMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; METABOLISM; MOUSE; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASCULITIS;

ANIMALS; ATHEROSCLEROSIS; AUTOANTIGENS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; FOAM CELLS; HEAT-SHOCK PROTEINS; HUMANS; LIPOPROTEINS, LDL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; MUSCLE, SMOOTH, VASCULAR; TUNICA INTIMA; VASCULITIS;

EID: 67649121931     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Review

References (173)

1. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002. 105:1135-1143.
2. Lyon C, Law R, Hsueh W. Minireview: Adiposity, Inflammation, and Atherogenesis. Endocrinology 2005; 144:2195-2200.
3. Stary H, Chandler A, Glagov S, Guyton J, Insull, W, Rosenfeld M, Schaffer S, Schwartz C, Wagner W, Wissler R. A definition of initial fatty streak and intermediate lesions of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Arterioscler Thromb 1994; 14: 840-856.
4. Stary H, Chandler A, Dinsmore R, Fuster V, Glagov S, Insull W, Rosenfeld M, Schwartz C, Wagner W, Wissler R. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Circulation 1995; 92:1355-1374.
5. White C, Brock T, Chang L, Craspo J, Briscoe P, Ku D, Bradley W, Gianturco S, Gore J, Freeman B, Tarpey M. Superoxide and Peroxynitrite in atherosclerosis. Proc Natl Acad. Sci USA 1994; 91:1044-1048.
6. Ayada K, Yokota K, Kobayashi K, Shoenfeld Y, Matsuura E, Oguma K. Chronic infections and atherosclerosis. Ann N Y Acad Sci. 2007; 1108:594-602.
7. Benagiano M, Azzurri A, Ciervo A, Amadei A, Tamburini C, Ferrari M, Telford J, Baldari C, Romagnani S, Cassone A, D'Elios M, Del Prete G. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA 2003. 100:6658-6663.
8. Lehr H, Sagban T, Ihling c, Zähringer U, Hungerer K, Blumrich M, Reifenberg K, Bhakdi S. Immunopathogenesis of atherosclerosis. Endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001; 104:914-920.
9. Rask-Madsen C, King G. Proatherosclerotic mechanisms involving protein kinase C in Diabetes and Insulin Resistance. Arterioscler Thromb Vasc Biol 2005; 25:487-496.
10. Wagenknecht L, Zaccaro D, Espeland M, Karter A, O'Leary D, Haffner S. Diabetes and progression of carotid atherosclerosis: The insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 2003; 23:1035-1041.
11. Chatzizisis Y, Coskun A, Jonas M, Edelman E, Feldman C, Stone P. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling. Molecular, Cellular, and vascular behavior. J Am Coll Cardiol 2007; 49: 2379-2393.
12. Larrousse M, Bragulat E, Segarra M, Sierra C, Coca A, De la Sierra A. Increased levels of atherosclerosis markers in Salt-sensitive hypertension. Am J Hypertension 2006; 19:87-93.
13. Skålén K, Gustafsson M, Rydberg E, Hultén L, Wiklund O, Innerarity T, Borén J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750-754.
14. Stocker R, Keaney J. Role of oxidative modifications in atherosclerosis. Physiol. Rev 2003; 84:1381-1478.
15. Tabas I, Williams K, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis. Update and therapeutic implications. Circulation 2007; 116: 1832-1844
16. Gawaz M, Langer H, May A. Platelets in inflammation and atherogenesis. J Clin Invest 2006; 115:3378-3384.
17. Cybulsky M, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutiérrez-Ramos J, Connelly P, Milstone D. A major role for VCAM-1 but not ICAM-1, in early atherosclerosis. J Clin Invest 2001; 107:1255-1262.
18. Henning B, Murarani P, Ramadass P, Watkins B, Toborek M. Fatty acid-mediated activation of vascular endothelial cells. Metabolism 2000; 49:1006-1013.
19. Williams K, Tabas I. The response-to-retention hypothesis of early atherogenesis. Atheroscler Thromb Vasc Biol 1995; 15:551-561.
20. Pentikäinen M, Öörni M, Ala-Korpela M, Kovanen P. Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 2000; 247:359-370.
21. Khalil M, Wagner W, Goldberg I. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 2211-2218.
22. Nakashima Y, Fujii H, Sumiyoshi S, Wight T, Sueishi K. Early human atherosclerosis. Accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007; 27:1159-1165.
23. Williams K, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998; 9:471-474.
24. Pillarisetti S, Paka L, Obunike J, Berglund L, Goldberg I. Subendothelial retention of lipoprotein (a). Evidence that reduced heparin sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 1997; 100:867-874.
25. Chait A, Wight T. Interaction of native and modified low-density lipoproteins with extracellular matrix. Cur Opin Lipidol 2000; 11:457-463.
26. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apoB lipoproteins with arterial proteoglycans significance and molecular basis. Atherosclerosis. 1998; 139:205-222.
27. Vijayagopal P, Srinivasan S, Radhakrishnamurthy B, Berenson G. Lipoprotein-proteoglycan complexes from atherosclerotic lesions promote cholesteryl ester accumulation in human monocytes/macrophages. Arterioscler Thromb Vasc Biol 1992; 12:237-249.
28. Talusan P, Bedri S, Yang S, Kattapuram T, Silva N, Roughley P, Stone J. Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics 2005; 4:1350-1357.
29. Nievelstein-Post P, Mottino G, Fogelman A, Frank J. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler Thromb 1994; 14: 1151-1161.
30. Tamminen M, Mottino G, Qiao J, Breslow J, Frank J. Ultrastructure of early lipid accumulation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19:847-853.
31. Kunjathoor V, Chiu D, O'Brien K, LeBoeuf R. Accumulation of Biglycan and Perlecan, but not Versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22:462-468.
32. Barón L, López F. Efecto de los proteoglicanos arteriales sobre la oxidación in vitro de LDL aislada de pacientes hipercolesterolémicos. Acta Cient Venez 2000; 51:211-222.
33. Aslanian A, Chapman H, Charo I. Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2005. 25:628-632.
34. Mahley R, Huang Y. Atherogenic remnant lipoproteins: Role of proteoglycans in trapping, transferring, and internalizing. J Clin Invest 2007; 117:94-98.
35. Hurt-Camejo E, Camejo G, Rosengren B, López F, Ahlstrom C, Fager G, Bondjers G. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb Vasc Biol 1992; 12:569-583.
36. Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution of atherogenesis. Arterioscler Thromb Vasc Biol 1997; 17:1011-1017.
37. Kaplan M, Aviram M. Retention of oxidized LDL by extracellular matrix proteoglycans leads to its uptake by macrophages an alternative approach to study lipoproteins cellular uptake. Arterioscler Thromb Vasc Biol 2001; 21:386-393.
38. Tabas I. Nonoxidative modifications of lipoproteins in atherogenesis. Annual Rev Nutrition 1999; 19:123-139.
39. Öörni K, Pentikäinen M, Ala-Korpela N, Kovanen P. Aggregation, fusion and vesicle formation of modified low density lipoprotein particles mechanism and effects on matrix interactions. J Lipid Res 2000; 41: 1703-1714.
40. Véniant M, Sullivan M, Kim S, Ambroziak P, Clu A, Wilson M, Hellerstein M, Rudel L, Walzem R, Young S. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B-100. J Clin Invest 2000; 106:1501-1510.
41. Schiopu A, Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares M, Shah P, Carlsson R, Nilsson J, Fredrikson G. Recombinant human antibodies against aldehyde-modifies apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004; 110:2047-2052.
42. Chyu K, Zhao X, Reyes O, Babbidge S, Dimayuga P, Yano J, Cercek B, Fredrikson G, Nilsson J, Shah P. Immunization using an apoB-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apoE (-/-) mice. Biochem Biophys Res Comm 2005; 338(4):1982-1989.
43. Fredrikson G, Schiopu A, Berglund G, Alm R, Shah P, Nilsson J. Autoantibody against the aminoacid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis. 2007; 194(2):e188-e192.
44. Wooton-Kee R, Boyanovsky B, Nasser M, De Williers W, Webb N. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arteroscler Thromb Vasc Biol 2004. 24: 762-767.
45. Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr. Pharm Des 2005; 11:3061-3072.
46. 2 in vascular disease. Circulation Res 2001; 89:298-304.
47. 2-modified low density lipoprotein promotes foam cell formation by a SR-A and CD36-independent process that involves cellular proteoglycans. J Biol Chem 2005; 280(38):32746-32752.
48. Öörni K, Posio P, Ala-Korpela M, Jauhiainen M, Kovanen P. Sphingomyelinase induces aggregation and fusion of small very low-density lipoprotein and intermediate-density lipoprotein particles and increases their retention to human arterial proteoglycans. Arterioscler Thromb Vasc Biol 2005; 25:1678-1683.
49. Nakashima Y, Chen Y, Kinukawa N, Sueishi K. Distributions of diffuse intimal thickening in human arteries: preferential expression in atherosclerosis-prone arteries from an early age. Virchows Arch 2002; 441:279-288.
50. De Winther M, Van Dijk K, Havekes L, Hofker M. Macrophage scavenger receptor class A. A multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20:290-297.
51. Gough P, Greaves D, Suzuki H, Hakkinen T, Hiltunen M, Turunen M, Ylä S, Kodama T, Gordon S. Analysis of macrophage Scavenger receptor (SR-A). Expression in human aortic atherosclerotic lesions. Arterioscler Thromb Vasc Bio. 1999; 19: 461-471.
52. Babaev V, Gleaves L, Carter K, Suzuki H, Kadama T, Fazio S, Linton M. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of Scavenger receptor-A. Arteriocler Thromb Vasc Biol 2000; 20:2593-2599.
53. Linton M, Babaev V, Cleaves A, Fazio S. A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation. J Biol Chem 1999; 274:19204-19210.
54. Herijgers N, Van Eck M, Groot P, Hoogerbrugge P, Van Berkel. Low density lipoprotein receptor of macrophages facilitates atherosclerotic lesion formation in C57B1/6 mice. Arterioscler Thromb Vasc Biol 2000; 20:1961-1967.
55. Overton C, Yancey P, Major A, Linton M, Fuzio S. Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse. Circ Res 2007; 100:670-677.
56. Whitman S, Argmann C, Sawyez C, Miller D, Hegele R & Huff M. Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-??. J Lipid Res 1999. 40:1017-1028.
57. Argman C, Van Den Diepstraten C, Sawyez G, Edward J, Hegele R, Wolfe B, Huff M. Transforming growth factor-beta 1 inhibits macrophages cholesterol ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol 2001; 21:2011-2018.
58. Tedgui A, Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev 2006; 86:515-581.
59. Fogelman A, Haberland M, Seager J, Hokom M, Edwards P. Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocytes-macrophages. J Lipid Res 1981; 22:1131-1141.
60. Traber M, Kayden H. Low density lipoprotein receptor activity in human monocytes-derived macrophages and its relation to atheromatous lesions. Proc Natl Sci Acad USA 1980; 77:5466-5470.
61. Rodríguez G. Acción de los complejos PGSC-LDL en la activación de las líneas celulares ACEI U937 y en macrófagos peritoneales de conejos hipercolesterolémicos. [Tesis Pre-Grado]. Cumaná, Universidad de Oriente, 2003.
62. Kruth H, Huang W, Ishii I, Zhang W. Macrophage foam cell formation with native low density lipoprotein. J Biol Chem 2002; 277:34573-34580.
63. Williams K, Fless G, Petrie K, Snyder M, Brocia R, Swenson T. Mechanism by which lipoprotein lipase alters cellular metabolism of lipoprotein (a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparin sulfate proteoglycans. J Biol Chem 1992; 267:13284-13292.
64. Babaev V, Patel M, Semenkovich C, Fazio S, Linton M. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem 2000; 275:26293-26299.
65. Gustafsson M, Levin M, Skålén K, Perman J, Fridén V, Jirholt P, Olofsson S, Fazio S, Linton M, Semenkovich C, Olivecrona G, Borén J. Retention of Low-Density Lipoprotein in Atherosclerotic Lesions of the Mouse. Evidence for a role of lipoprotein lipase. Circ Res 2007; 101:777-783.
66. Loeffler B, Heeren J, Blaeser M, Radner H, Kayser D, Aydin B, Merkel M. Lipoprotein lipase-facilitated uptake of LDL is mediated by the LDL receptor. J Lipid Res 2007; 48:288-298.
67. Kim J, Territo M, Wayner E, Carlos T, Parhami F, Smith C, Haberland M, Fogelman A, Berliner J. Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Arterioscler Thromb 1994; 14:427-433.
68. Quinn M, Parthasarathy S, Steinberg D. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci USA 1985; 82:5949-5953.
69. Quinn M, Parthasarathy S, Fong L, Steinberg D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84:2995-2998.
70. Stemme S, Faber B, Holm J, Wiklund O, Witztum J, Hansson G. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl. Acad Sci USA 1995; 92:3893-3897.
71. Horkko S, Binder C, Shaw P, Chang M, Silverman G, Palinski W, Witztum J. Immunological responses to oxidized LDL. Free Radical. Biol Med 2000; 28:1771-1779.
72. Janabi M, Yamashita S, Hinaro K, Sakai N, Hiraoka H, Matsumoto K, Zhang Z, Nogaki S, Matsuzawa Y. Oxidized LDL-induced NF-κB activation and subsequent expression of proinflammatory genes are defective in monocyte-derivated macrophages from CD36-deficient patients. Arterioscler Thromb Vasc Biol 2000; 20:1953-1960.
73. Liao F, Andalibi A, De Beer F, Fogelman A, Lusis A. Minimally modified low density lipoprotein is biologically active in vivo in mice. J Clin Invest 1991; 87: 2253-2257.
74. Frostegard J, Huang Y, Ronnelid J, Schafer-Elinder L. Platelet-activating factor rand oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997. 17:963-968.
75. Bochkov V, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier W, Hofer E, Binder B, Leitinger N. Oxidized phospholipids stimulate tissue factor expression in human endothelial cell via activation of ERK/EGR-1 and Ca (++)/NFAT. Blood 2002; 99:199-206.
76. Cui M, Penn M, Chisolm G. Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. J Biol Chem 1999; 274:32795-32802.
77. Nishi E, Kume N, Ueno Y, Ochi H, Moriwaki H, Kita T. Lysophosphatidylcholine enhances cytokine-induced interferon gamma expression in human T lymphocytes. Circ Res 1998; 83:508-515.
78. Liu-Wu Y, Hurt-Camejo E, Wiklund O. Lysophosphatidylcholine induces the production of IL-1 beta by human monocytes. Atherosclerosis 1998; 137:351-357.
79. Kume N, Cybulsky M, Gimbrone M. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90:1138-1144.
80. Zhu Y, Lin J, Liao H, Verna L, Stemerman M. Activation of ICAM-1 promoter by Lysophosphatidylcholine: Possible involvement of protein tyrosine kinases. Biochim Biophys Acta 1997; 1345: 93-98.
81. Takabe W, Kanai Y, Chairoungdua A, Shibata N, Toi S, Kobayashi M, Kodama T, Noguchi N. Lysophosphatidylcholine enhances cytokine production of endothelial cells via induction of L-type amino acid transporter 1 and cell surface antigen 4F2. Arterioscler Thromb Vasc Biol 2004; 24:1640-1645.
82. Takahara N, Kachiwagi A, Maegawa H, Shigeta Y. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 1996; 45:559-564.
83. Murugesau G, Sandhya R, Gerber C, Mukhopadhyay C, Ransohoff R, Chisolm G, Kottke-Marchant K. Lysophosphatidylcholine regulates human microvasculature endothelial cell expression of chemokines. J Mol Cell Cardiol 2003; 35:1375-1384.
84. Rong J, Berman J, Taubman M, Fisher E. Lysophosphatidylcholine stimulates monocytes chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2002; 22:1617-1623.
85. Ramos C, Huo Y, Lung U, Ghosh S, Manka D, Saarembock I, Luj K. Direct demonstration of P-selectin and VCAM-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein E-deficient mice. Circ Res 1999; 84:1237-1244.
86. Huo Y, Hafezi-Moghadam A, Luj K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segmetn-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res 2000; 87:153-159.
87. Rao R, Yang L, García-Cárdena G, Luscinskas F. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 2007; 101:234-247.
88. Nakashima Y, Raines E, Plump A, Breslow J, Ross R. Up-regulation of VCAM-1 and ICAM-1 at atherosclerosisprone sites on the endothelium in the Apo-E-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18: 842-851.
89. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff B, Cybulski M. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85:199-207.
90. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, Inoue N, Hirata K, Matsukawa A, Morishita R, Kaneda Y, Yokoyama M. Local overexpression of monocytes chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesions: Synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002; 22:115-120.
91. Richardson M, Hadcock S, De Reske M, Cybulsky M. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb 1994. 14:760-769.
92. Cha J, Jeong M, Bae H, Han J, Jeong S, Lim Y, Kim S, Kim J. Activated platelets induce secretion of interleukin-1 beta, monocytes chemotactic protein-1, and macrophage inflammatory protein-1 alpha and surface expression of intercellular adhesion molecule-1 on cultured endothelial cells. J Korean Med Sci 2000. 15:273-278.
93. Reckless J, Rubin E, Verstuyft J, Metcalfe J, Grainger D. Monocyte chemoattractant protein-1 but not tumor necrosis factor α is correlated with monocytes infiltration in mouse lipid lesions. Circulation 1999; 99:2310-2316.
94. Kowala M, Recce R, Beyer S, Gu C, Valentine M. Characterization of atherosclerosis in LDL receptor Knockout mice: Macrophage accumulation correlates with rapid and sustained expression of aortic MCP-1/JE. Atherosclerosis 2000; 149:323-330.
95. Barlic J, Murphy P. Chemokine regulation of atherogenesis. J Leukoc Biol 2007; 82:226-236.
96. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot C, Young S, Rollins B, Charo I. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103:773-778.
97. Veillard N, Steffens S, Pelli G, Lu B, Kwak B, Gerard C, Charo I, Mach F. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005; 112:870-878.
98. Viedt C, Vogel J, Athanasiou T, Shen W, Orth S, Kubler W, Kreuzer J. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol 2002; 22:914-920.
99. Sakai M, Kobori S, Miyazaki A, Horiuchi B. Macrophage proliferation in atherosclerosis. Curr Opin Lipidol 2000; 11:503-509.
100. Rosenfeld M, Ylaherttuala S, Lipton B, Ord A, Witztum J, Steinberg D. Macrophage colony-stimulating factor messenger RNA and protein in atherosclerotic lesions of rabbits and human. Am J Pathol 1992; 140:291-300.
101. Smith J, Trogau E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995; 92:8264-8268.
102. Qiao J, Tripathi J, Mishra N, Cai Y, Tripathi S, Wang X, Imes S, Fishbein M, Clinton S, Libby P, Lusis A, Rajavashisth T. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150:1687-1699.
103. Jones N, Reagan J, Willingham M. The pathogenesis of foam cell formation. Modified LDL stimulates uptake of Co-incubated LDL via macropinocytosis. Arterioscler. Thromb Vasc Biol 2000; 20:773-781.
104. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88:877-887.
105. Mallat Z, Tedgui A. The role of transforming growth factor beta in atherosclerosis: Novel insights and future perspectives. Curr Opin Lipidol 2002; 13:523-529.
106. Østered B, Bjørklid E. Role of monocytes in atherogenesis. Physiol Rev 2003; 83:1069-1112.
107. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Imunol 1993; 54:1-78.
108. Rattazi M, Puato M, Fuggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: Culprits or passive by standers?. J Hypertens 2003; 21:1787-1803.
109. Paul A, Ko K, Li L, Yechoor V, McCrory M, Szalai A, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apo-lipoprotein E-deficient mice. Circulation 2004; 109:647-655.
110. Jovinge S, Hamsten A, Tornvall P, Proudler A, Båvenholm P, Erickson C. Evidence of a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998; 47:113-118.
111. Rajavashisth T, Xu X, Jovinge S, Meisel S, Xu X, Chai N, Fishbein M, Kaul S, Cercek B, Sharifi B, Shah P. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators. Circulation. 1999. 99:3103-3109.
112. Lee W, Kim S, Lee Y, Lee B, Kwon B, Song H, Kwon B, Park J. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001; 21:2004-2010.
113. Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of Tumor Necrosis Factor- α reduces atherosclerosis in apolipoprotein-E knockout mice. Arterioscler Thromb Vasc Biol 2004; 24:2137-2142.
114. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1 β decreases the severity of atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:656-660.
115. Robertson A, Hansson G. T cells in atherogenesis: For better or for worse?. Arterioscler Thromb Vasc Biol 2006; 26:2421-2432.
116. Huber S, Sakkinen P, Conze D, Hardin N, Tracy R. Inteleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999; 19:2364-2367.
117. Davenport P, Tipping P. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163:1117-1125.
118. Swirski F, Pittet M, Kircher M, Aikawa E, Jaffer F, Libby P, Wissleder R. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci USA 2006; 103:10340-10345.
119. Song L, Leung C, Schindler C. Lymphocytes are important in early atherosclerosis. J Clin. Invest. 2001. 108: 251-259.
120. Ludewing B, Krebs P, Scandella E. Immunopathogenesis of atherosclerosis. J Leukoc Biol 2004; 76:300-306.
121. Businaro R, Digregorio M, Riganò R, Profumo G, Buttari B, Leone S, Salvati B, Capoano R, D'Amati G, Fumagalli L. Morphological analysis of cell subpopulations within carotid atherosclerotic plaque. Ital J Anat Embryol 2005; 110 (2 Suppl. 1):109-115.
122. Zhou X, Stemme S, Hansson G. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996; 149:359-366.
123. Zhou X, Caligiuri G, Hamsten A, Lefvert A, Hansson G. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:108-114.
124. Zhou X, Robertson A, Hjerpe C, Hansson G. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:864-870.
125. Pockley A. Heat shock proteins, inflammation, and cardiovascular disease. Circulation 2002; 105:1012-1017.
126. Mandal K, Jahangiri M, Xu Q. Autoimmunity to heat shock proteins in atherosclerosis. Autoimmune Rev 2004; 3:31-37.
127. Benagiano M, D'Delios M, Amedei A, Azzurri A, Van Der Zee R, Ciervo A, Rombolà R, Romagnani S, Cassone A, Del Prete A. Human 60-KDA heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J Immunol 2005; 174: 6509-6517.
128. Rigano R, Profumo E, Buttari B, Tagliani A, Petrone L, D' Amati G, Ippoliti F, Capoano R, Fumagalli L, Salvati B, Busirano R. Heat shock proteins and autoimmunity in patients with carotid atherosclerosis. Ann N Y Acad Sci 2007; 1107:1-10.
129. Daugherty A, Pure E, Delfel-Butteiger D, Chen S, Leferovich J, Roselaar S, Rader D. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E -/- mice. J Clin Invest 1997; 100:1575-1580.
130. Reardon C, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz G. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21:1011-1016.
131. Goldsby R, Kindt T, Osborne B. Immunology. Fourth edition. W.H Freeman and Company. N.Y. USA. 2000. 670 pp.
132. Frostergard J, Ulfgren A, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson G. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145:33-43.
133. Gupta S, Pablo A, Jiang X, Wang N, Tall R, Schindler C. IFN-gamma potentiates atherosclerosis in apoE knockout mice. J Clin Invest 1997; 99:2752-2761.
134. Leon M, Zuckerman S. Gamma interferon: A central mediator in atherosclerosis. Inflamm Res 2005; 54:395-411.
135. Linton M, Major A, Fazio S. Proatherogenic role for NK cells revealed. Arterioscler Thromb Vasc Biol 2003; 24: 992-994.
136. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren H, Hansson G, Berne G. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004. 199:417-422.
137. Whitman S, Rateri D, Szilvassy S, Yokoyama W, Daugherty A. Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol 2004; 24:1049-1054.
138. Nakai Y, Iwabuchi K, Fujii S, Ishimore N, Dastsoodol N, Nakayama T, Taniguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer, L, Onoe K. Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104:2051-2059.
139. Puren A, Fantuzzi G, Gu V, Su M, Dinarello C. Interleukin-18 (INF gamma-inducing factor) induces IL-8 and IL-1 beta via TNF alpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998; 101:711-721.
140. Gerdes N, Sukhova G, Libby P, Reynolds R, Young J, Schönbeck U. Expression of Interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenesis. J Exp Med 2002; 195:245-257.
141. Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of INF- γ and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol 2005; 25:791-796.
142. Binder C, Hartvigsen K, Chang M, Miller M, Broide D, Palinski W, Curtiss L, Corr M, Witstum J. IL-5 links adaptative and natural immunity specific for epítopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114:427-437.
143. Pinderski L, Fischbein M, Subbanagounder G, Fischbein M, Kubo N, Cheroutre H, Curtis L, Berliner J, Boisvert W. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90:1064-1071.
144. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukun-10. J Exp Med 1991; 174:1549-1555.
145. Lunscinskas F, Kansas G, Ding H, Pizcueta P, Schleiffenbaum B, Tedder T, Gimbrone M. Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, beta(1)-integrins, and beta(2)-integrins. J Cell Biol 1994; 125:1417-1427.
146. Lee Y, Kuhn H, Henning B, Neish A, Toborek M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 2001; 33:83-94.
147. Lee Y, Henning B, Toborek M. Redox-regulated mechanism of IL-4 induced MCP-1 expression inhuman vascular endothelial cells. Am J Physiol Heart Circ Physiol 2003; 284:H185-H192.
148. Rollins B, Pober J. Interleukin-4 induces the synthesis and secretion of mcp-1/je by human endothelial cells. Am J Pathol 1991; 138:1315-1319.
149. Ridker P, Rifai N, Stamfer M, Hennekens C. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
150. Ridker P, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor- α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-2153.
151. Luc G, Bard J, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart J, Ducimetiere P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME study. Arterioscler Thromb Vasc Biol 2003; 23:1255-1261.
152. Hwang S, Ballantyne C, Sharrett R, Smith L, Davis C, Gotto A, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1 and E-Selectin in carotid atherosclerosis and incident coronary heart disease cases: The atherosclerosis risk in communities (ARIC) Study. Circulation 1997; 96:4219-4225.
153. Ridker P, Hennekens C, Roitman-Johnson B, Stampfer M, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998; 351:88-92.
154. Ridker P, Buring J, Rifai N. Soluble P-Selectin and the risk of future
155. Ridker P, Hennekens C, Buring J, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
156. Mendall M, Strachan D, Butland B, Ballan L, Morris J, Sweetnam D, Elwood P. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21:1584-1590.
157. Blackburn R, Giral P, Bruckert E, André J, Gonbert S, Bernard M, Chapman M, Turpin G. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol 2001; 21:1962-1968.
158. Khera A, Lemos J, Peshock R, Lo H, Stanek H, Murphy S, Wians F, Grundy S, McGuire D. Relation ship between C-reactive protein and sub-clinical atherosclerosis. The Dallas Heart Study. Circulation 2006; 113:38-43.
159. Tzoulaki I, Murray G, Lee A, Rumley A, Lowe G, Fowkes F. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh artery study. Circulation 2005; 112:976-983.
160. Packard R, Libby P. Inflammation in atherosclerosis: From vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54:24-38.
161. Torzewski M, Rist C, Mortensen R, Zwaka T, Bienek M, Waltenberger J, Koenig W, Schmitz G, Hombach V, Torzewski J. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000; 20:2094-2099.
162. Zwaka T, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001; 103:1194-1197.
163. Pasceri V, Cheng J, Willerson J, Yeh E. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103:2531-2534.
164. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van De Werf F. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21:844-848.
165. Goncalves I, Gronholdt M, Söderberg I, Ares M, Nordestgoard B, Bentzon J, Fredrikson G, Nilsson J. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques. Arterioscler Thromb Vasc Biol 2005; 25:1250-1255.
166. Vaarala O. Antibodies to oxidized LDL. Lupus. 2000. 9: 202-205.
167. Oei H, Van Der Meer I, Hofman A, Koudstaal P, Stifnen T, Breteler M, Witteman J. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation 2005; 111:570-575.
168. Yang E, McConnell J, Lennon R, Barsness G, Pumper G, Hartman S, Rihal C, Lerman L, Lerman A. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2006; 26:106-111.
169. Ridker P, Cannon C, Morrow D, Rifai N, Rose L, McCabe C, Pfeffer M, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-28.
170. Napoli C, D' Armiento F, Mancini F, Postiglione A, Witztum J, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by mathernal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100:2680-2690.
171. McGill H, McMahan A, Herderick E, Malcom G, Tracy R, Strong J. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 2000; 72(suppl):1307S-15S.
172. Spagnoli L, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med 2007; 48:1800-1815.
173. Faxon D, Fuster V, Libby P, Beckman J, Hiatt W, Thompson R, Topper J, Annes B, Rundback J, Fabunmi R, Robertson R, Loscalzo J. Atherosclerotic vascular disease conference: Writing group III: Pathophysiology. Circulation 2004; 109: 2617-2625.